Nabriva Therapeutics, Plc
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$201Kgeneral payments (2019-2025)
$0.00research payments (2019-2025)
4,912clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Christian Sandrock | Sacramento, CA | Internal Medicine | $6,701.00 |
| Thomas File | Akron, OH | Infectious Disease | $3,336.79 |
| David Bullard | Cleveland, OH | Emergency Medicine | $2,602.24 |
| Patrick Flume | Charleston, SC | Pulmonary Disease | $2,203.00 |
| Henry Dorkin | Boston, MA | Pediatric Pulmonology | $2,203.00 |
| Paul Planet | Philadelphia, PA | Pediatric Infectious Diseases | $2,203.00 |
| Marianne Muhlebach | Chapel Hill, NC | Pediatric Pulmonology | $2,203.00 |
| Michael Konstan | Cleveland, OH | Pediatric Pulmonology | $2,203.00 |
| David Nichols | Seattle, WA | Pediatric Pulmonology | $2,203.00 |
| Rohit Gupta | Philadelphia, PA | Pulmonary Disease | $2,158.35 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.